F

or India’s biggest drug makers, the Trump administration offers a mix of promise and peril.

On one hand, these companies supply many lower-cost generics to the United States, a key advantage as President Trump accuses most brand-name drug makers of “getting away with murder” when it comes to pricing. But Indian drug makers also fret the Trump administration will place them at a disadvantage with any policies that favor domestic jobs stemming from products made in the US.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • And such quality issues continue, as evidenced in a letter dated this month. [Warning Letter 320-17-28] That will be a hard slog:
    “These findings indicate that your quality unit is not exercising its responsibilities.
    In your response, you admitted that a “gap exist[ed] in the Quality Assurance department” concerning document control. “

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.